SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L. Neuen, Meg Jardine, Vlado Perkovic et al.|The Lancet Diabetes & Endocrinology|2019Cited by 870
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney diseaseW Bakker, J W Rood, Hiddo J.L. Heerspink et al.|Nephrology Dialysis Transplantation|2025Cited by 18